Acute Kidney Injury Clinical Trial
— WARNING KDOfficial title:
Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust
Kidney disease in its chronic or acute form shares many risk factors for initiation, progression and prognosis with an increase in morbidity and mortality, the length of hospitalization and the cost associated with stages of increasing severity. Its overall estimated prevalence in the general population is 13% and 0.5% from stage 4, for which referral to a nephrologist is recommended to reduce mortality, slow progression of renal disease and better prepare for treatment by renal replacement. Acute kidney injury (AKI) is defined as a sudden increase in serum creatinine (Scr) with a prognostic classification of increasing severity. The population with chronic kidney disease (CKD) is often hospitalized and is frequently complicated by AKI, however CKD is asymptomatic for a long time, requiring structure screening in populations at risk. Performing Scr assays during hospitalization is an opportunity to screen patients with severe CRD or ARI requiring specialized treatment during and after hospitalization. A nephrological opinion is recommended for patients with severe CKD and AKI. Based on preliminary studies "MRC GARD" (NCT02938611) and "ARI TARGET" (NCT03192189), the study investigators identified the frequency of patients with increased Scr corresponding to stages ≥4 of CKD and to stage1b of ARI during their hospitalization. They found that 50% of patients hospitalized with a severe AKI had a CKD prior to their hospitalization. The use of dosages of Scr during hospitalization has been studied for AKI but without targeting high-risk subgroups and with discordant results. The study investigators plan to carry out a pragmatic study to show that an intervention combining alerts with Scr dosage to detect severe forms of CRD and AKI during hospitalization associated with the systematic intervention of a specialized dedicated team associating nephrologist and pharmacist to the scale of a GHT will improve patient and renal survival 1 year after screening.
Status | Recruiting |
Enrollment | 1680 |
Est. completion date | December 16, 2024 |
Est. primary completion date | December 16, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The patient or their representative must have given their free and informed consent oral consent - The patient must be a member or beneficiary of a health insurance plan - Patient living in the Gard, France - Patient with abnormal dose: - Severe grade 4 or 5 CKD suspected in front of a GFR <30 mL / min / 1.73m2 persisting during hospitalization. - Acute kidney injury > stage 1 defined by an increase in serum creatinine of at least 100% in less than 7 days or a threshold greater than 354 µmol / l. Exclusion Criteria: - The subject is participating in another category I interventional study, or is in a period of exclusion determined by a previous study - It is impossible to give the subject or their representative informed information - The patient is under safeguard of justice or state guardianship - Patient is pregnant, parturient or breastfeeding. - Patient unable to express consent - Patient with Stage 1 Acute kidney injury defined by an increase in serum creatinine of more than 26 µmol / l in less than 48 hours or a 50% increase in serum creatinine within 7 days. - Patient with stage 1 to 3 CKD (glomerular filtration rate (GFR)> 30 mL / min / 1.73m2) - Palliative/end-of-life patients - Patients who died within 72 hours of receiving the signal - Patients hospitalized in nephrology after an emergency room visit only - Patients under guardianship. |
Country | Name | City | State |
---|---|---|---|
France | CH Alès Cévennes | Alès | |
France | CH Bagnols-sur-Cèze | Bagnols-sur-Cèze | |
France | CHU de Nîmes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Information taken from national database | 12 Months | |
Secondary | Need for renal support | yes / no. Information available in the SNDS database and the REIN register. | 12 Months | |
Secondary | Mortality | Information taken from national database | 30 days | |
Secondary | Emergency start of renal support management | Yes/no with exact date noted if yes. Information available in the REIN register | 12 Months | |
Secondary | Oriented of patient towards autonomous support techniques | Yes/no. Information available in the REIN register | 12 Months | |
Secondary | Which autonomous support techniques used | renal transplant or home dialysis | 12 Months | |
Secondary | Use of an arteriovenous fistula during the first session | Yes/no | 12 Months | |
Secondary | Duration of initial hospitalization | Days | 12 Months | |
Secondary | Duration of rehospitalizations | Days | 12 Months | |
Secondary | Causes of rehospitalizations | Information taken from SNDS database | 12 Months | |
Secondary | The rate of patients with stage =4 CKD followed by a nephrologist | Data-collection via the medical file on visit(s) to the nephrologist during hospitalization; after discharge from hospital via data collected in the SNDS database | 12 Months | |
Secondary | Rate of patients with at least one inappropriate drug prescription for renal function | Inclusion | ||
Secondary | Rate of patients with at least one inappropriate drug prescription for renal function | 3 Months | ||
Secondary | Rate of patients with at least one inappropriate drug prescription for renal function | 12 Months | ||
Secondary | Prevalence of drug prescriptions slowing down the progression of the kidney disease and treating complications | Inclusion | ||
Secondary | Prevalence of drug prescriptions slowing down the progression of the kidney disease and treating complications | 3 Months | ||
Secondary | Prevalence of drug prescriptions slowing down the progression of the kidney disease and treating complications | 12 Months | ||
Secondary | Estimation of the incremental cost-efficiency ratio | ratio of la difference in cost and the difference in life expectancy between the two strategies | 12 Months | |
Secondary | National scale estimation of costs avoided | Total costs of healthcare consumption and the cost of setting up the device in the two management strategies | 12 Months | |
Secondary | Evaluation of the satisfaction carers of patients in the interventional group during hospitalization | 6-item custom questionnaire on 5-point Likert scale with free comment section | end of the interventional strategy phase (minimum 3 months, maximum 12 months) | |
Secondary | Evaluation of the satisfaction doctors of patients in the interventional group during hospitalization | 5-item custom questionnaire on 5-point Likert scale with free comment section | end of the interventional strategy phase (minimum 3 months, maximum 12 months) | |
Secondary | Evaluation of the satisfaction doctors of patients in the interventional group during hospitalization | 5-item custom questionnaire on 5-point Likert scale with free comment section | 12 Months | |
Secondary | Evaluation of patient satisfaction of patients in the interventional group | 3-item custom questionnaire on 5-point Likert scale free comment section | end of the interventional strategy phase (minimum 3 months, maximum 12 months) | |
Secondary | Evaluation of patient satisfaction of patients in the interventional group | 3-item custom questionnaire on 5-point Likert scale free comment section | 12 months | |
Secondary | Evaluate the implementation of the "WARNING KD" management model at individual facilities according to the Template for Intervention Description and Replication (TIDieR) checklist. | 12-item checklist | Over the study - maximum 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |